For patients with Stage IV metastatic NSCLC, multimodal chemotherapy administered intravenously in combination with target therapy with the anti-vascular endothelial growth factor (VEGF) mAb, bevacizumab or with immunotherapy with anti-PD–L1 mAb represents the first line strategy. Here, VEGFA is linked to non-small cell lung carcinoma.